Literature DB >> 12657678

Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

Zhao-Xue Yu1, Shi-Hua Li, Joy Evans, Ajay Pillarisetti, He Li, Xiao-Jiang Li.   

Abstract

Huntington's disease (HD) mouse models that express N-terminal huntingtin fragments show rapid disease progression and have been used for developing therapeutics. However, light microscopy reveals no significant neurodegeneration in these mice. It remains unclear how mutant huntingtin induces neurodegeneration. Using caspase staining, terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling, and electron microscopy, we observed that N171-82Q mice, which express the first 171 aa of mutant huntingtin, displayed more degenerated neurons than did other HD mouse models. The neurodegeneration was also evidenced by increased immunostaining for glial fibrillary acidic protein and ultrastructural features of apoptosis. R6/2 mice, which express exon 1 of mutant huntingtin, showed dark, nonapoptotic neurons and degenerated mitochondria associated with mutant huntingtin. In HD repeat knock-in mice (HdhCAG150), which express full-length mutant huntingtin, degenerated cytoplasmic organelles were found in both axons and neuronal cell bodies in association with mutant huntingtin that was not labeled by an antibody to huntingtin amino acids 342-456. Transfection of cultured cells with mutant huntingtin revealed that an N-terminal huntingtin fragment (amino acids 1-208 plus a 120 glutamine repeat) caused a greater increase in caspase activity than did exon 1 huntingtin and longer huntingtin fragments. These results suggest that context-dependent neurodegeneration in HD may be mediated by different N-terminal huntingtin fragments. In addition, this study has identified neurodegenerative markers for the evaluation of therapeutic treatments in HD mouse models.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657678      PMCID: PMC6742008     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

Review 2.  Energetics in the pathogenesis of neurodegenerative diseases.

Authors:  M F Beal
Journal:  Trends Neurosci       Date:  2000-07       Impact factor: 13.837

3.  Caspase-8 is required for cell death induced by expanded polyglutamine repeats.

Authors:  I Sánchez; C J Xu; P Juo; A Kakizaka; J Blenis; J Yuan
Journal:  Neuron       Date:  1999-03       Impact factor: 17.173

4.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

5.  Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells.

Authors:  C L Wellington; R Singaraja; L Ellerby; J Savill; S Roy; B Leavitt; E Cattaneo; A Hackam; A Sharp; N Thornberry; D W Nicholson; D E Bredesen; M R Hayden
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

6.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.

Authors:  V O Ona; M Li; J P Vonsattel; L J Andrews; S Q Khan; W M Chung; A S Frey; A S Menon; X J Li; P E Stieg; J Yuan; J B Penney; A B Young; J H Cha; R M Friedlander
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

7.  A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Authors:  J G Hodgson; N Agopyan; C A Gutekunst; B R Leavitt; F LePiane; R Singaraja; D J Smith; N Bissada; K McCutcheon; J Nasir; L Jamot; X J Li; M E Stevens; E Rosemond; J C Roder; A G Phillips; E M Rubin; S M Hersch; M R Hayden
Journal:  Neuron       Date:  1999-05       Impact factor: 17.173

8.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

9.  Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice.

Authors:  V C Wheeler; J K White; C A Gutekunst; V Vrbanac; M Weaver; X J Li; S H Li; H Yi; J P Vonsattel; J F Gusella; S Hersch; W Auerbach; A L Joyner; M E MacDonald
Journal:  Hum Mol Genet       Date:  2000-03-01       Impact factor: 6.150

10.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.

Authors:  M Turmaine; A Raza; A Mahal; L Mangiarini; G P Bates; S W Davies
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

View more
  95 in total

Review 1.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

2.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

3.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

4.  Raft-like microdomains play a key role in mitochondrial impairment in lymphoid cells from patients with Huntington's disease.

Authors:  Laura Ciarlo; Valeria Manganelli; Paola Matarrese; Tina Garofalo; Antonella Tinari; Lucrezia Gambardella; Matteo Marconi; Maria Grasso; Roberta Misasi; Maurizio Sorice; Walter Malorni
Journal:  J Lipid Res       Date:  2012-07-06       Impact factor: 5.922

5.  Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.

Authors:  Shamayra Smail; Dalbir Bahga; Brittnee McDole; Kathleen Guthrie
Journal:  Chem Senses       Date:  2016-01-18       Impact factor: 3.160

6.  Lack of minocycline efficiency in genetic models of Huntington's disease.

Authors:  Stéphane Mievis; Marc Levivier; David Communi; Gilbert Vassart; Jacques Brotchi; Catherine Ledent; David Blum
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

7.  Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

Authors:  Jodi L McBride; Shilpa Ramaswamy; Mehdi Gasmi; Raymond T Bartus; Christopher D Herzog; Eugene P Brandon; Lili Zhou; Mark R Pitzer; Elizabeth M Berry-Kravis; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

8.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Authors:  Elizabeth J Slow; Rona K Graham; Alexander P Osmand; Rebecca S Devon; Ge Lu; Yu Deng; Jacqui Pearson; Kuljeet Vaid; Nagat Bissada; Ronald Wetzel; Blair R Leavitt; Michael R Hayden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

Review 9.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

10.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms.

Authors:  Jennifer Bradford; Ji-Yeon Shin; Meredith Roberts; Chuan-En Wang; Xiao-Jiang Li; Shihua Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.